These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30144431)

  • 1. Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.
    Moreau R; Elkrief L; Bureau C; Perarnau JM; Thévenot T; Saliba F; Louvet A; Nahon P; Lannes A; Anty R; Hillaire S; Pasquet B; Ozenne V; Rudler M; Ollivier-Hourmand I; Robic MA; d'Alteroche L; Di Martino V; Ripault MP; Pauwels A; Grangé JD; Carbonell N; Bronowicki JP; Payancé A; Rautou PE; Valla D; Gault N; Lebrec D;
    Gastroenterology; 2018 Dec; 155(6):1816-1827.e9. PubMed ID: 30144431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial.
    Grangé JD; Roulot D; Pelletier G; Pariente EA; Denis J; Ink O; Blanc P; Richardet JP; Vinel JP; Delisle F; Fischer D; Flahault A; Amiot X
    J Hepatol; 1998 Sep; 29(3):430-6. PubMed ID: 9764990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
    Fernández J; Ruiz del Arbol L; Gómez C; Durandez R; Serradilla R; Guarner C; Planas R; Arroyo V; Navasa M
    Gastroenterology; 2006 Oct; 131(4):1049-56; quiz 1285. PubMed ID: 17030175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
    Lebrec D; Thabut D; Oberti F; Perarnau JM; Condat B; Barraud H; Saliba F; Carbonell N; Renard P; Ramond MJ; Moreau R; Poynard T;
    Gastroenterology; 2010 May; 138(5):1755-62. PubMed ID: 20102716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites.
    Sandhu BS; Gupta R; Sharma J; Singh J; Murthy NS; Sarin SK
    J Gastroenterol Hepatol; 2005 Apr; 20(4):599-605. PubMed ID: 15836710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial.
    Yim HJ; Suh SJ; Jung YK; Yim SY; Seo YS; Lee YR; Park SY; Jang JY; Kim YS; Kim HS; Kim BI; Um SH
    Am J Gastroenterol; 2018 Aug; 113(8):1167-1176. PubMed ID: 29946179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
    Elfert A; Abo Ali L; Soliman S; Ibrahim S; Abd-Elsalam S
    Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1450-1454. PubMed ID: 27512927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial.
    Pande C; Kumar A; Sarin SK
    Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):831-9. PubMed ID: 22522141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis.
    Kedarisetty CK; Anand L; Bhardwaj A; Bhadoria AS; Kumar G; Vyas AK; David P; Trehanpati N; Rastogi A; Bihari C; Maiwall R; Garg HK; Vashishtha C; Kumar M; Bhatia V; Sarin SK
    Gastroenterology; 2015 Jun; 148(7):1362-70.e7. PubMed ID: 25749502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.
    Novella M; Solà R; Soriano G; Andreu M; Gana J; Ortiz J; Coll S; Sàbat M; Vila MC; Guarner C; Vilardell F
    Hepatology; 1997 Mar; 25(3):532-6. PubMed ID: 9049193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial.
    Casper M; Mengel M; Fuhrmann C; Herrmann E; Appenrodt B; Schiedermaier P; Reichert M; Bruns T; Engelmann C; Grünhage F; Lammert F;
    Trials; 2015 Mar; 16():83. PubMed ID: 25887140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis-study protocol for an interventional randomised controlled trial.
    Crocombe D; Ahmed N; Balakrishnan I; Bordea E; Chau M; China L; Corless L; Danquah V; Dehbi HM; Dillon JF; Forrest EH; Freemantle N; Gear DP; Hollywood C; Hunter R; Jeyapalan T; Kallis Y; McPherson S; Munteanu I; Portal J; Richardson P; Ryder SD; Virk A; Wright G; O'Brien A
    Trials; 2022 Sep; 23(1):812. PubMed ID: 36167573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial.
    Ginés P; Rimola A; Planas R; Vargas V; Marco F; Almela M; Forné M; Miranda ML; Llach J; Salmerón JM
    Hepatology; 1990 Oct; 12(4 Pt 1):716-24. PubMed ID: 2210673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.
    Solà E; Solé C; Simón-Talero M; Martín-Llahí M; Castellote J; Garcia-Martínez R; Moreira R; Torrens M; Márquez F; Fabrellas N; de Prada G; Huelin P; Lopez Benaiges E; Ventura M; Manríquez M; Nazar A; Ariza X; Suñé P; Graupera I; Pose E; Colmenero J; Pavesi M; Guevara M; Navasa M; Xiol X; Córdoba J; Vargas V; Ginès P
    J Hepatol; 2018 Dec; 69(6):1250-1259. PubMed ID: 30138685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.
    Sersté T; Melot C; Francoz C; Durand F; Rautou PE; Valla D; Moreau R; Lebrec D
    Hepatology; 2010 Sep; 52(3):1017-22. PubMed ID: 20583214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients.
    Lontos S; Shelton E; Angus PW; Vaughan R; Roberts SK; Gordon A; Gow PJ
    J Dig Dis; 2014 May; 15(5):260-7. PubMed ID: 24612987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients.
    Mostafa T; Badra G; Abdallah M
    Turk J Gastroenterol; 2015 Mar; 26(2):163-9. PubMed ID: 25835116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.
    Assem M; Elsabaawy M; Abdelrashed M; Elemam S; Khodeer S; Hamed W; Abdelaziz A; El-Azab G
    Hepatol Int; 2016 Mar; 10(2):377-85. PubMed ID: 26660707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bacterial infections in liver cirrhosis].
    Papp M; Farkas A; Udvardy M; Tornai I
    Orv Hetil; 2007 Mar; 148(9):387-95. PubMed ID: 17344166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity.
    Wong F; Watson H; Gerbes A; Vilstrup H; Badalamenti S; Bernardi M; Ginès P;
    Gut; 2012 Jan; 61(1):108-16. PubMed ID: 21836029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.